News
PMVP
1.700
+3.03%
0.050
BUZZ-Australia's Premier Investments among top losers on ASX 200
Australia's Premier Investments among top losers on ASX 200 index. Shares of Premier Investments PMV.AX fall as much as 2.9% to A$31.085. Morningstar says PMV's underlying profit after tax fell 6%. Brokerage Jarden raises target price for the stock.
Reuters · 2d ago
Weekly Report: what happened at PMVP last week (0318-0322)?
Weekly Report · 4d ago
Oppenheimer Remains a Hold on PMV Pharmaceuticals (PMVP)
TipRanks · 03/19 11:55
PMV Pharmaceuticals PYNNACLE Phase I Data Of Rezatapopt In Advanced Ovarian Cancer Featured In Oral Presentation At 2024 SGO Annual Meeting On Women's Cancer
Phase 1 analysis from the PYNNACLE Phase 1/2 study showed promising efficacy of rezatapopt in patients with advanced ovarian cancer harboring a TP53 Y220C mutation. Seven patients achieved a confirmed partial response with a seven-month median duration of response. Rez atapopt is a first-in-class precision oncology therapy.
Benzinga · 03/18 20:02
Weekly Report: what happened at PMVP last week (0311-0315)?
Weekly Report · 03/18 09:05
Weekly Report: what happened at PMVP last week (0304-0308)?
Weekly Report · 03/11 09:05
Big Pharma patent cliffs seen fueling oncology M&A this year
Big Pharma patent cliffs seen fueling oncology M&A this year. Around $182B in revenue is at risk over the next four years due to patent expirations. Cantor Fitzgerald sees between five and 17 acquisition deals for oncologists in 2014. The global market for cancer drugs is expected to grow from $180B in 2022 to $323B in 2028.
Seeking Alpha · 03/10 17:08
PMV Pharmaceuticals Price Target Maintained With a $5.00/Share by HC Wainwright & Co.
Dow Jones · 03/07 12:21
HC Wainwright & Co. Reiterates Buy on PMV Pharma, Maintains $5 Price Target
Benzinga · 03/07 12:11
PMV Pharmaceuticals: Buy Rating Affirmed Amid Strong Financials and Promising Clinical Prospects
TipRanks · 03/07 11:27
Weekly Report: what happened at PMVP last week (0226-0301)?
Weekly Report · 03/04 09:05
PMV Pharmaceuticals reports FY results
PMV Pharmaceuticals, Inc. Reports FY results Mar. 01, 2024. Net loss for the year ended December 31, 2023, was $69 million compared to $73.3 million for the same period in 2022. The company's stock is down 2.7% in the last week.
Seeking Alpha · 03/01 15:35
Oppenheimer Keeps Their Hold Rating on PMV Pharmaceuticals (PMVP)
TipRanks · 03/01 12:48
TD Cowen Reaffirms Their Buy Rating on PMV Pharmaceuticals (PMVP)
TipRanks · 02/29 23:35
PMV Pharmaceuticals FY23 EPS $(1.44) Vs $(1.61) YoY
As of December 31, 2023, PMV Pharma had $228.6 million in cash, cash equivalents, and marketable securities. Research and development expenses were $55.9 million for the year ended 2023. The Company had a net loss of $69.0 million for fiscal year 2022.
Benzinga · 02/29 21:19
Press Release: PMV Pharmaceuticals Reports Full Year 2023 Financial Results and Corporate Highlights
PMV Pharmaceuticals reports financial results for the fourth quarter and full year ended December 31, 2023. The company continues to make significant progress with rezatapopt, a first-in-class precision oncology investigational therapy in patients with advanced solid tumors with a p53 Y220C mutation. The Phase 2 portion of the company's clinical trial remains on track to initiate in the first quarter of 2024. Cash, cash equivalents, and marketable securities of $228.6 million are expected to extend PMV's cash runway to the end of 2026.
Dow Jones · 02/29 21:01
Press Release: PMV Pharmaceuticals Reports Full -2-
December 31, 2012, is the last day for the company to report its financial results for the period ending December 31, 2013. The company has a total of $1.2 billion in assets and $1 billion in liabilities. The number of assets is based on the number of shares of the company and the value of its liabilities.
Dow Jones · 02/29 21:01
Weekly Report: what happened at PMVP last week (0219-0223)?
Weekly Report · 02/26 09:06
Weekly Report: what happened at PMVP last week (0212-0216)?
Weekly Report · 02/19 09:06
Weekly Report: what happened at PMVP last week (0205-0209)?
Weekly Report · 02/12 09:05
More
Webull provides a variety of real-time PMVP stock news. You can receive the latest news about Pmv Pharmaceuticals, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About PMVP
PMV Pharmaceuticals, Inc. is a precision oncology company, which is engaged in discovery and development of small molecule, tumor-agnostic therapies targeting p53. p53 is a tumor suppressor protein known as the guardian of the genome, and normal, or wild type, p53 has the ability to eliminate cancer cells. It is leveraging its precision oncology platform to develop a pipeline of orally available, potent and highly selective small molecule product candidates that target p53 mutations or other p53-related cancers. Its lead product candidate, PC14586 (rezatapopt), is an orally available small molecule designed to potently and selectively correct p53 misfolding caused by a specific p53 mutation, Y220C, while sparing wild type p53. In preclinical studies, PC14586 has shown selective on-target activity, which functions in cells with the p53 Y220C mutation and exhibited robust anti-tumor activity evidenced by potent tumor growth inhibition and strong tumor regression as a single agent.